Published by Uma Rajagopal
Posted on February 21, 2022
The global narcolepsy drugs market has been under the spotlight recently as the awareness about sleep disorders grows. The pandemic brought with it a sudden wave of sleeping disorders as many found their daily schedules disrupted. Psychological distress added to the gamut of issues, which has raised awareness about narcolepsy too. As the focus on improving lifestyle in the post-pandemic world continues, analysts at Fairfield Market Research estimate the sentiment will drive the global narcolepsy drugs market.
According to the research report, the global narcolepsy drugs market is expected to be worth US$6,588.0 Mn by the end of 2026 from US$3,875.1 Mn in 2021. As the market grows with the positive sentiment of awareness and acceptance of drugs, it is poised to register a CAGR of 11.2% between 2026 and 2021.
Looking For a Sample Copy of This Report? Request the Same Here: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market/request-sample
Narcolepsy with Cataplexy to Achieves Fastest-Growing Status
According to the Narcolepsy Network, about 70% of patients with narcolepsy experience cataplexy. It manifests in a sudden loss of muscle strength, resulting in slurred speech, jaw-dropping, drooping eyelids, and involuntary twitching amongst others. Cataplexy remains the confirming and conclusive diagnostic measurement of narcolepsy, making narcolepsy with cataplexy or type 1 narcolepsy the fastest-growing segment in the global market. Patients can experience this debilitating condition at a later stage as well. By the end of 2026, type 1 narcolepsy will hold 65% of the global market, predicts Fairfield Market Research.
Sodium Oxybate Remain Undisputed Drug for Treating Narcolepsy
Sodium oxybate is the unrivalled leading drug in the global narcolepsy drugs market. By the end of 2021, this drug is expected to hold a market share of 52% in the global market. This dominance can be attributed to its ability to treat cataplexy and excessive daytime sleepiness (EDS) is expected to bode well for the segment. Furthermore, it is the only drug approved by the US Food and Drug Administration (FDA) for treating cataplexy. Sold under the brand name Xyrem, sodium oxybate is best known to reduce the frequency of sleep attacks in patients with narcolepsy.
Stimulants such as modafinil, amodafonil, antidepressents, and tricuclical are also used in combination to treat narcolepsy. However, sodium oxybate’s results remain far better, giving the drug class an edge over others.
Do You Have Any Query or Specific Requirement? Request Customization of Report: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market/request-customization
North America to Hold Lion’s Share in Global Narcolepsy Drugs Market
The National Institute of Neurological Disorders and Stroke, U.S., estimates that about 200,000 people living in the U.S. alone suffer from narcolepsy. Relatively higher awareness about the disorder, access to better healthcare, and increasing expenditure on medical needs are expected to drive the regional market between 2021 and 2026. Fairfield Market Research indicates that North America narcolepsy market will exhibit a CAGR of 11.3% from 2021 to 2025. Europe is expected to follow suit as the region experiences a demographic change that is dictated by information-centric patients.
Meanwhile, sleep disorders brought on by shift-based business models are expected to generate a demand for narcolepsy drugs in Asia Pacific. An overall increase in stress levels is also expected to underpin the growth of Asia Pacific narcolepsy drugs market.
Some of the leading players in the global narcolepsy drugs market are Avadel Pharmaceuticals plc, Harmony Biosciences, Arena Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., GrayMark Healtcare Inc., Ligand Pharmaceuticals, Inc., and Shionogi Inc.
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
Follow Us: LinkedIn
Explore more articles in the Research Reports category
